Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs) Abstract #2055

Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth
Aim(s): However, there is limited evidence for the antiproliferative effect of this strategy
Materials and methods: Progression-free survival(PFS) was assessed in a large cohort of 116 patients on 3-weekly SSAs(as monotherapy).All patients were previously on maximum doses of SSAs every 4 weeks.Univariate(UVA) and multivariate(MVA) analyses were performed to identify factors affecting PFS
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result